Literature DB >> 26770458

Diagnostic accuracy of ascitic cholesterol concentration for malignant ascites: a meta-analysis.

Hong Zhu1, Yongchun Shen2, Kai Deng3, Xia Liu1, Yaqin Zhao1, Taiguo Liu1, Ying Huang4.   

Abstract

Many studies have investigated whether ascitic cholesterol can aid in diagnosis of malignant related ascites (MRA), and the results have varied considerably. To gain a more reliable answer to this question, we meta-analyzed the literature on using ascitic cholesterol as diagnostic tests to help identify MRA. Literature databases were systematically searched for studies examining accuracy of ascitic cholesterol for diagnosing MRA. Data on sensitivity, specificity, positive/negative likelihood ratio (PLR/NLR), and diagnostic odds ratio (DOR) were pooled using random effects models. Summary receiver operating characteristic (SROC) curves and area under the curve (AUC) were used to summarize overall test performance. At last, our meta-analysis included 8 studies involving 743 subjects. Summary estimates for ascitic cholesterol in the diagnosis of MRA were as follows: sensitivity, 0.82 (95% CI 0.78 to 0.86); specificity, 0.90 (95% CI 0.87 to 0.93); PLR, 9.24 (95% CI 4.58 to 18.66); NLR, 0.16 (95% CI 0.08 to 0.32); and DOR, 66.96 (95% CI 18.83 to 238.11). The AUC was 0.96. The ascitic cholesterol level is helpful for the diagnosis of MRA. Nevertheless, the results of ascitic cholesterol assays should be interpreted in parallel with the results of traditional tests and clinical information.

Entities:  

Keywords:  Cholesterol; diagnosis; malignant ascites; meta-analysis

Year:  2015        PMID: 26770458      PMCID: PMC4694358     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  16 in total

1.  The identification of neoplastic cells in serous effusions; critical analysis of smears from 2,029 persons.

Authors:  N C FOOT
Journal:  Am J Pathol       Date:  1956 Sep-Oct       Impact factor: 4.307

2.  The utility of lactate dehydrogenase isoenzyme pattern in the diagnostic evaluation of malignant and nonmalignant ascites.

Authors:  Alper Sevinc; Ramazan Sari; Ersin Fadillioglu
Journal:  J Natl Med Assoc       Date:  2005-01       Impact factor: 1.798

3.  Value of combined detection of AFU and TCH in differential diagnosis between malignant and non-tuberculous benign ascites.

Authors:  Hong Zhang; Feng Li; Qun Wei; Yu-Fei Zhu
Journal:  Med Oncol       Date:  2010-11-02       Impact factor: 3.064

4.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Int J Surg       Date:  2010-02-18       Impact factor: 6.071

5.  Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites.

Authors:  Daye Cheng; Bin Liang; Hong Kong
Journal:  Med Oncol       Date:  2011-05-10       Impact factor: 3.064

6.  Diagnostic value of ascitic fluid cholesterol levels in the prediction of malignancy.

Authors:  P B Mortensen; S D Kristensen; A Bloch; B A Jacobsen; S N Rasmussen
Journal:  Scand J Gastroenterol       Date:  1988-11       Impact factor: 2.423

7.  Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence.

Authors:  A L Gerbes; D Jüngst; Y N Xie; W Permanetter; G Paumgartner
Journal:  Cancer       Date:  1991-10-15       Impact factor: 6.860

8.  Value of ascitic lipids in the differentiation between cirrhotic and malignant ascites.

Authors:  D Jüngst; A L Gerbes; R Martin; G Paumgartner
Journal:  Hepatology       Date:  1986 Mar-Apr       Impact factor: 17.425

9.  Diagnosis of malignant ascites. Comparison of ascitic fibronectin, cholesterol, and serum-ascites albumin difference.

Authors:  M Prieto; M J Gómez-Lechón; M Hoyos; J V Castell; D Carrasco; J Berenguer
Journal:  Dig Dis Sci       Date:  1988-07       Impact factor: 3.199

10.  The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews.

Authors:  Penny Whiting; Anne W S Rutjes; Johannes B Reitsma; Patrick M M Bossuyt; Jos Kleijnen
Journal:  BMC Med Res Methodol       Date:  2003-11-10       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.